#1 Clinical Trials Search in Europe

Perflubutane

Perflubutane, also known by the brand name Sonazoid, is an ultrasound contrast agent being studied in various clinical trials for its potential to improve diagnostic imaging and cancer detection. This article explores the use of perflubutane in ongoing research for conditions like liver cancer, endometrial cancer, breast cancer, and portal hypertension in children.

Table of Contents

What is Perflubutane?

Perflubutane, also known by its brand names Sonazoid and Perfluorobutane, is a medical contrast agent used in ultrasound imaging[1]. It belongs to a class of substances called ultrasound contrast agents, which help improve the quality and clarity of ultrasound images. Perflubutane is considered a second-generation contrast agent, meaning it’s more advanced and effective than earlier versions[2].

How Does Perflubutane Work?

Perflubutane consists of tiny gas-filled bubbles called microbubbles. These microbubbles are about the size of red blood cells and contain a chemically stable gas called perfluorobutane. The microbubbles are surrounded by a hard shell made of a substance called phosphatidylserine sodium[2].

When injected into the body, these microbubbles circulate in the bloodstream. During an ultrasound examination, the microbubbles interact with the sound waves, creating strong echoes. This interaction enhances the visibility of blood vessels and organs on the ultrasound images, allowing doctors to see details more clearly[3].

Medical Uses of Perflubutane

Perflubutane has several medical applications, primarily in diagnostic imaging. Some of its uses include:

  • Liver Imaging: Perflubutane is particularly useful for examining the liver. It can help detect and characterize liver lesions, which are abnormal areas in the liver that might indicate disease. The contrast agent accumulates in special liver cells called Kupffer cells, allowing doctors to distinguish between healthy liver tissue and potential tumors[1].
  • Cancer Detection: Perflubutane is being studied for its potential in detecting various types of cancer, including:
    • Hepatocellular carcinoma (liver cancer)[1]
    • Endometrial cancer (cancer of the uterus lining)[2]
    • Breast cancer[3]
    • Cervical, vaginal, and vulvar cancers[4]
    • Esophageal cancer[5]
  • Sentinel Lymph Node Detection: Perflubutane is being investigated for its ability to identify sentinel lymph nodes. These are the first lymph nodes where cancer is likely to spread from a primary tumor. Accurate detection of these nodes is crucial for cancer staging and treatment planning[3][4][5].
  • Portal Hypertension Assessment: Researchers are studying the use of Perflubutane in evaluating portal hypertension, a condition where blood pressure is increased in the portal vein that carries blood to the liver. This is particularly important in children with liver disease[6].

How is Perflubutane Administered?

Perflubutane is typically administered through an intravenous (IV) injection. The exact dose and method of administration may vary depending on the specific medical procedure and the patient’s condition. Some common methods include:

  • Injection into a vein (intravenous)[2]
  • Injection under the skin (subdermal)[3]
  • Injection around or into a tumor[5]

The dosage is usually calculated based on the patient’s body weight. For example, one study used a dose of 0.015 mL/kg of body weight[2].

Safety and Side Effects

Perflubutane is generally considered safe for use in medical imaging. However, like all medical procedures, there can be potential side effects. The exact nature and frequency of side effects are still being studied, especially in different patient populations such as children[6].

It’s important to note that contrast agents like Perflubutane are administered under medical supervision, and patients are monitored for any adverse reactions during and after the procedure.

Ongoing Research

Several clinical trials are currently underway to further investigate the uses and effectiveness of Perflubutane in various medical conditions. These studies aim to:

  • Improve cancer detection and staging techniques[1][2][3]
  • Enhance the accuracy of sentinel lymph node detection in different types of cancer[4][5]
  • Develop non-invasive methods for assessing portal hypertension in children[6]

These ongoing studies may lead to expanded uses of Perflubutane in the future, potentially improving diagnostic accuracy and patient care in various medical fields.

Aspect Details
Primary Uses Enhancing ultrasound imaging for cancer detection and characterization
Cancer Types Studied Liver cancer, endometrial cancer, breast cancer, esophageal cancer
Other Applications Sentinel lymph node detection, guiding ablation therapy, assessing portal hypertension
Administration Methods Intravenous injection/infusion, subdermal injection, peritumoral injection
Key Features Long-lasting contrast enhancement, accumulation in liver Kupffer cells
Potential Benefits Improved lesion detection, better tumor characterization, non-invasive pressure estimation
Safety Considerations Ongoing monitoring in clinical trials, specific side effects not detailed in provided information

FAQ

  • What is Perflubutane and how does it work? Perflubutane is an ultrasound contrast agent composed of microbubbles containing chemically stable gas. When injected, it enhances ultrasound imaging by generating echoes at specific frequencies, allowing for better visualization of tissues and blood flow.
  • In which medical conditions is Perflubutane being studied? Perflubutane is being investigated in clinical trials for various conditions, including hepatocellular carcinoma (liver cancer), endometrial cancer, breast cancer, esophageal cancer, and portal hypertension in children.
  • How is Perflubutane administered in clinical trials? The administration method varies depending on the study, but it's typically given as an intravenous injection or infusion. In some trials, it's injected subdermally or around tumor sites for specific imaging purposes.
  • What are the potential benefits of using Perflubutane in diagnostic imaging? Perflubutane may improve the detection and characterization of tumors, help identify sentinel lymph nodes in cancer patients, and assist in guiding procedures like tumor ablation. It may also aid in non-invasive assessment of conditions like portal hypertension.
  • Are there any known side effects or risks associated with Perflubutane use? While specific side effects are not detailed in the provided trial information, the safety and tolerability of Perflubutane are being closely monitored in these studies. As with any medical procedure, potential risks and side effects should be discussed with a healthcare provider.

Ongoing Clinical Trials on Perflubutane

  • Study on Using Ultrasound with Perflubutane and Laxative for Detecting Crohn’s Disease in Patients

    Recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study on Using Perflubutane for Sentinel Node Detection in Patients with Breast Cancer, Melanoma, or Head and Neck Cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Safety and Effectiveness of Intravenous Sonazoid for Contrast-Enhanced Liver Ultrasound in Children with Focal Liver Lesions

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Germany Italy

  • Study on Using Perflubutane in Ultrasound Imaging for Patients Needing Lymphatic Imaging

    Not yet recruiting

    4 1 1 1
    Investigated drugs:
    Finland

  • Study on Sonoporation-Enhanced Treatment with Gemcitabine, Nab-Paclitaxel, and FOLFIRINOX for Patients with Inoperable Pancreatic Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Norway

Glossary

  • Perflubutane: An ultrasound contrast agent composed of microbubbles containing chemically stable gas, used to enhance ultrasound imaging.
  • Sonazoid: A brand name for perflubutane, used as an ultrasound contrast agent in diagnostic imaging.
  • Hepatocellular Carcinoma (HCC): The most common type of primary liver cancer, often occurring in people with chronic liver diseases.
  • Sentinel Lymph Node (SLN): The first lymph node or group of nodes draining a cancer site, important for determining if cancer has spread beyond the primary tumor.
  • Contrast-Enhanced Ultrasound (CEUS): An ultrasound technique that uses contrast agents like perflubutane to improve image quality and provide more detailed information about blood flow and tissue characteristics.
  • Kupffer Phase: A delayed phase of contrast-enhanced ultrasound imaging where the contrast agent is taken up by Kupffer cells in the liver, allowing for better visualization of liver lesions.
  • Ablation Therapy: A minimally invasive treatment that uses heat (radiofrequency or microwave) to destroy cancer cells.
  • Portal Hypertension: Increased blood pressure in the portal venous system, often a complication of liver disease.
  • Subharmonic Aided Pressure Estimation (SHAPE): A non-invasive ultrasound technique used to estimate pressure in blood vessels, particularly useful in assessing portal hypertension.
  • Fine-Needle Aspiration (FNA): A diagnostic procedure where a thin needle is used to extract cells or fluid from a suspicious area for examination.

References

  1. https://clinicaltrials.gov/study/NCT05068076
  2. https://clinicaltrials.gov/study/NCT04961775
  3. https://clinicaltrials.gov/study/NCT02652923
  4. https://clinicaltrials.gov/study/NCT05105087
  5. https://clinicaltrials.gov/study/NCT03578224
  6. https://clinicaltrials.gov/study/NCT04720456